HUP9801384A2 - Klostridium perfringens vakcina - Google Patents

Klostridium perfringens vakcina

Info

Publication number
HUP9801384A2
HUP9801384A2 HU9801384A HUP9801384A HUP9801384A2 HU P9801384 A2 HUP9801384 A2 HU P9801384A2 HU 9801384 A HU9801384 A HU 9801384A HU P9801384 A HUP9801384 A HU P9801384A HU P9801384 A2 HUP9801384 A2 HU P9801384A2
Authority
HU
Hungary
Prior art keywords
toxin
subject
cells
well
expression systems
Prior art date
Application number
HU9801384A
Other languages
English (en)
Inventor
Peer Lyng Frandsen
Ruund Philip Antoon Maria Segers
Nicolas Robin Waterfield
Jeremy Mark Wells
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of HU9801384D0 publication Critical patent/HU9801384D0/hu
Publication of HUP9801384A2 publication Critical patent/HUP9801384A2/hu
Publication of HUP9801384A3 publication Critical patent/HUP9801384A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány Clőstridiűm perfringens b-tőxin detőxifikált imműnőgénszármazékaira, valamint annak imműnőgén fragmenseire vőnatkőzik,amelyek közös jellemzője, hőgy a b-tőxin aminősav-szekvenciában, a vadtípűsú b-tőxinban elő nem főrdűló műtációt hőrdőznak. A találmánytárgyát képezik tővábbá, ilyen b-tőxinőkat kódőló gének, és ilyen b-tőxinőkat expresszáló expressziós rendszerek. Ezen felül a találmánytárgyáhőz tartőznak natív b-tőxint expresszáló bakteriális expressziósrendszerek. Végül a találmány tárgyát képezik Clőstridiűm perfringensb-tőxin genetikailag detőxifikált imműnőgén származé-kain alapűlóvakcinák, valamint az ilyen vakcinák előállítására szőlgáló eljárás. ŕ
HU9801384A 1997-06-20 1998-06-19 Clostridium perfringens vaccine HUP9801384A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201888 1997-06-20

Publications (3)

Publication Number Publication Date
HU9801384D0 HU9801384D0 (en) 1998-08-28
HUP9801384A2 true HUP9801384A2 (hu) 1999-03-29
HUP9801384A3 HUP9801384A3 (en) 2001-11-28

Family

ID=8228464

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801384A HUP9801384A3 (en) 1997-06-20 1998-06-19 Clostridium perfringens vaccine

Country Status (17)

Country Link
US (1) US6610300B1 (hu)
EP (1) EP0892054B1 (hu)
JP (1) JP4234232B2 (hu)
KR (1) KR19990007306A (hu)
CN (2) CN101914145A (hu)
AT (1) ATE346931T1 (hu)
AU (1) AU743498B2 (hu)
BR (1) BR9802361A (hu)
CA (1) CA2235445A1 (hu)
DE (1) DE69836520T2 (hu)
DK (1) DK0892054T3 (hu)
ES (1) ES2276448T3 (hu)
HU (1) HUP9801384A3 (hu)
NZ (1) NZ330749A (hu)
PT (1) PT892054E (hu)
TW (1) TWI221847B (hu)
ZA (1) ZA985393B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2768747B1 (fr) * 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
EP1560935A2 (en) * 2002-11-15 2005-08-10 VIB vzw Self-containing lactobacillus strain
JP5410759B2 (ja) 2005-11-29 2014-02-05 アクトジェニックス・エヌブイ 抗原に対する粘膜寛容の誘導
WO2007126816A2 (en) 2006-03-30 2007-11-08 Embrex, Inc. Methods and compositions for vaccination of poultry
US7732187B2 (en) 2006-04-17 2010-06-08 Intervet Inc. Recombinant attenuated clostridium organisms and vaccine
EP2086578B1 (en) * 2006-11-20 2012-01-11 Intervet International B.V. Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
EP2125010B1 (en) 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
PL2164862T3 (pl) * 2007-06-08 2015-12-31 Australian Poultry Crc Pty Ltd Toksyna netb z clostridium
CA2699435A1 (en) 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110882384B (zh) * 2019-12-17 2024-01-26 天康生物制药有限公司 猪流行性腹泻-猪梭菌性肠炎二联亚单位的口服疫苗及制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB958574A (en) * 1959-11-23 1964-05-21 Wellcome Found Clostridium perfringens ª‰-toxoid vaccines
SE7809880L (sv) * 1978-09-20 1980-03-21 Zemlyakova Valentina Porfiriev Vaccin for profylax och behandling av clostridiosis hos djur och fjederfe
ES2185631T3 (es) * 1992-05-20 2003-05-01 Secr Defence Vacunas de clostridium perfringens.
US5538851A (en) * 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
GB9522611D0 (en) 1995-11-03 1996-01-03 Brooks Holdings Ltd Improvements in and relating to a security closure for a door opening
GB9605222D0 (en) * 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines

Also Published As

Publication number Publication date
HU9801384D0 (en) 1998-08-28
DE69836520T2 (de) 2007-06-06
CN1215729A (zh) 1999-05-05
AU743498B2 (en) 2002-01-24
NZ330749A (en) 1999-10-28
CN101914145A (zh) 2010-12-15
ES2276448T3 (es) 2007-06-16
JP4234232B2 (ja) 2009-03-04
CA2235445A1 (en) 1998-12-20
JPH11103872A (ja) 1999-04-20
DE69836520D1 (de) 2007-01-11
US6610300B1 (en) 2003-08-26
DK0892054T3 (da) 2007-04-02
BR9802361A (pt) 2000-01-11
EP0892054A1 (en) 1999-01-20
KR19990007306A (ko) 1999-01-25
ATE346931T1 (de) 2006-12-15
PT892054E (pt) 2007-02-28
ZA985393B (en) 1999-02-17
EP0892054B1 (en) 2006-11-29
TWI221847B (en) 2004-10-11
HUP9801384A3 (en) 2001-11-28
AU7308798A (en) 1998-12-24

Similar Documents

Publication Publication Date Title
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
HUP9801384A2 (hu) Klostridium perfringens vakcina
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
SG152917A1 (en) Neisseria meningitidis antigens
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
MY119003A (en) Bacterial antigens and vaccine compositions
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
AU1463097A (en) Helicobacter pylori bacterioferritin
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
MX9708426A (es) Polipeptido hk2 de variante estable.
SG146662A1 (en) Method
AU5554301A (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
AUPQ347199A0 (en) Novel polypeptide fragments
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
NO20011263D0 (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
AR004191A1 (es) Polipeptidos para inducir inmunidad protectora contra la tuberculosis, molecula de adn que los codifica, un vector de expresion, una celula huesped,una composicion farmaceutica, una vacuna, una proteina de fusion, un metodo para detectar la tuberculosis y kit de diagnostico.
AR003102A1 (es) Vacuna de env-glicoproteina para la proteccion de infeccion de htlv-i y ii

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: INTERVET INTERNATIONAL B.V., NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished